The two primary endpoints were OS, assessed in the intent-to-treat population, for durvalumab plus chemotherapy versus chemotherapy alone and for durvalumab plus tremelimumab plus chemotherapy versus chemotherapy alone [11]. Secondary endpoints included PFS, objective response rate (ORR; unconfirmed) [bo...